Last reviewed · How we verify
Placebo (human albumin 1%) — Competitive Intelligence Brief
phase 3
Plasma volume expander / Colloid
Critical Care / Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo (human albumin 1%) (Placebo (human albumin 1%)) — Biotest. Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo (human albumin 1%) TARGET | Placebo (human albumin 1%) | Biotest | phase 3 | Plasma volume expander / Colloid |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Plasma volume expander / Colloid class)
- Biotest · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo (human albumin 1%) CI watch — RSS
- Placebo (human albumin 1%) CI watch — Atom
- Placebo (human albumin 1%) CI watch — JSON
- Placebo (human albumin 1%) alone — RSS
- Whole Plasma volume expander / Colloid class — RSS
Cite this brief
Drug Landscape (2026). Placebo (human albumin 1%) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-human-albumin-1. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab